drugset / Trial / NCT04058067
To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of Chinese patients with visual impairment due to Diabetic Macular Edema.
Timeline
- Start
- 2019-08-23
- Primary completion
- 2023-01-31
- Completion
- 2023-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | — |
| Subject | Brolucizumab | Other / unclassified | 6 mg | — |